Non-GMP synthesis of compounds. POP: 9/19/24-9/18/25.
Active Purchase Order Awarded Last action
- Contract number
- 75N95024P00615
- Awardee
-
Curia Global Inc. UEI ELCNZCS8GEA3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $884,003
Award facts
- Opportunity
-
- Neurodegenerative Disease Research, Non-GMP Synthesis of Compounds Special Notice · 75N95024Q00460 · Posted Jul 18, 2024
- Contract value 50% obligated
-
- $884,002.80 Current, with exercised options
- $1,785,511.20 Potential, with all options
- Completion date 43% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Buffalo, NY 14203, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $300,503 | |
| Exercise an Option | $291,750 | |
| Original award | $291,750 |
About this award
The National Institute on Drug Abuse (NIDA), on behalf of the National Institute of Neurological Disorders and Stroke (NINDS), issued a purchase order to Curia Global Inc. (doing business as Amri) on September 19, 2024, for non-GMP synthesis of compounds, with a ceiling value of $1,785,511.20.
The order supports a medicinal chemistry discovery program focused on identifying molecules that bind the KIAA0203 protein for potential Alzheimer's drug development. Work is performed in Buffalo, New York, with a period of performance from September 19, 2024, through September 18, 2025, and an ultimate completion date of September 18, 2029. The procurement was issued as a follow-on to an existing contract; continuation with the same vendor and facilities was necessary to maintain research data integrity. The requirement calls for synthesis of up to 100 compounds in 2–10 milligram quantities under non-GMP conditions.
In fiscal year 2024, the order invoiced $292 thousand against 3.5 FTEs and 7,181 contractor hours, with a derived government-paid hourly rate of $40.63 per hour. The prime self-performed all reported hours with no subcontractors.
Quick answers
Who was awarded contract 75N95024P00615?
75N95024P00615 was awarded to Curia Global Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 19, 2024.
How much is contract 75N95024P00615 worth?
The government has obligated $884,003 on 75N95024P00615. Its potential value, with all options, is $1,785,511.
Was contract 75N95024P00615 competed?
The extent of competition for 75N95024P00615 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award